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ABSTRACT 32 
Background 33 
Immunodeficiency syndromes (acquired/congenital/iatrogenic) are known to increase 34 
Hodgkin’s lymphoma (HL) risk, but the effect of allergic immune dysregulation and 35 
corticosteroids are poorly understood.  36 
Objective 37 
To assess the risk of HL associated with allergic disease (asthma, eczema and allergic 38 
rhinitis) and corticosteroid use. 39 
Methods 40 
We conducted a case-control study using the UK Clinical Practice Research Datalink 41 
(CPRD) linked to hospital data. Multivariable logistic regression investigated associations 42 
between allergic diseases and HL after adjusting for established risk factors. Potential 43 
confounding or effect modification by steroid treatment were examined. 44 
Results 45 
1,236 cases of HL were matched to 7,416 controls. Immunosuppression was associated with 46 
6-fold greater odds of HL (Adjusted Odds Ratio (AOR), 6.18; 95%CI, 3.04–12.57), with 47 
minimal change after adjusting for steroids. Any prior allergic disease or eczema alone were 48 
associated with 1.4-fold increased odds of HL (AOR, 1.41; 95%CI, 1.24–1.60; AOR, 1.41; 49 
95%CI, 1.20–1.65, respectively). These associations decreased but remained significant 50 
after adjustment for steroids (AOR, 1.25; 95%CI, 1.09–1.43; AOR, 1.27; 95%CI, 1.08–1.49, 51 
respectively). There was no effect modification by steroid use. Previous steroid treatment 52 
was associated with 1.4-fold greater HL odds (AOR, 1.38; 95%CI, 1.20–1.59).  53 
Conclusions 54 
In addition to established risk factors (immunosuppression and infectious mononucleosis), 55 
allergic disease and eczema are risk factors for developing HL. This association is only 56 
partially explained by steroids, which are associated with increased HL risk. These findings 57 
add to the growing evidence that immune system malfunction, following allergic disease or 58 
immunosuppression, is central to HL development. 59 
 60 
KEY MESSAGES 61 
• Allergic disease, especially eczema, is associated with increased risk of Hodgkin’s 62 
lymphoma 63 
• Corticosteroid treatment is associated with increased Hodgkin’s lymphoma risk 64 
• Immune system malfunction, following allergic disease or immunosuppression, is 65 
central to HL development 66 
 67 
CAPSULE SUMMARY 68 
Our data support that prior allergic disease, especially eczema, and corticosteroid treatment 69 
increase the risk of developing incident Hodgkin’s lymphoma before the age of 50. Immune 70 
system malfunction is central to Hodgkin’s lymphoma development.  71 
 72 
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INTRODUCTION 82 
Hodgkin’s lymphoma (HL) is a cancer of the lymphatic system and is the most common 83 
cancer in teenagers and young adults (TYAs) worldwide (1, 2). A number of conditions with 84 
disordered immune regulation have been associated with an increased risk of developing HL 85 
in TYAs. These include infectious mononucleosis (IM) following Epstein Barr virus (EBV) 86 
infection (3-7), HIV infection (8-10), immunosuppressive therapy (11-17) and several 87 
autoimmune diseases such as multiple sclerosis (18), systemic lupus erythematosus (19) 88 
and rheumatoid arthritis (20, 21). Certain HLA genes that are responsible for the regulation 89 
of the immune system in humans have also been associated with increased risk of HL in 90 
genetic studies (22, 23). These findings together provide support for immune system 91 
malfunction playing a central role in development of HL. 92 
The antigenic stimulation hypothesis has been suggested to explain the underlying 93 
mechanism for immune system malfunction in HL development. It proposes that conditions 94 
with chronic immune stimulation predispose individuals to developing haematological 95 
malignancies, such as multiple myeloma, non-Hodgkin’s lymphoma and leukaemia, by 96 
promoting development of randomly occurring pro-oncogenic mutations in actively dividing 97 
immune cells (24-26). There is a growing body of evidence supporting this hypothesis and 98 
showing that a number of immune-related cancers, including leukaemia, occur as a 99 
consequence of immune system malfunction in early life (27-29). 100 
Allergic diseases, including asthma, eczema and allergic rhinitis, are amongst the 101 
commonest perpetrators of chronic immune stimulation. Few studies have investigated the 102 
link between allergic diseases and HL and the results have been conflicting and inconclusive 103 
(24, 25, 30-35). Previous studies have been small scale or relied on small numbers of 104 
exposed individuals and therefore may not have had the power to detect associations. No 105 
studies have been conducted using electronic health records from primary care, where 106 
allergic disease is predominantly diagnosed and managed, or in the UK population which 107 
has one of the highest rates of both HL in TYAs and allergic disease worldwide (36, 37).  108 
Corticosteroids are a mainstay in the treatment of allergic diseases. Their use is often 109 
reserved for more severe cases that have not responded to first-line conventional therapies 110 
and they primarily act through suppression of the immune response. Any association 111 
between allergic disease and HL could therefore be intertwined with the effect of steroids: 112 
Steroid use could modify any effect (as they are a marker of allergic disease severity); or 113 
confound it (as they are used in treatment of a range of immune-related diseases that may 114 
also be risk factors for HL). It is important to therefore consider this interplaying role in any 115 
study of allergic disease. Some studies have identified steroids as a risk factor for 116 
developing lymphoma (38-40), although others have found no increased risk (41, 42); more 117 
importantly, it is unclear whether steroid use is an independent risk factor, a marker of 118 
allergic disease severity, or a proxy for other immune-related diseases. Furthermore, many 119 
of the studies did not differentiate between the types of lymphoma or focused only on topical 120 
steroids, adding to the uncertainty surrounding the role of steroid treatment and HL risk.  121 
In this study we used linked primary care electronic health records to determine if individuals 122 
with a history of allergic disease (asthma, eczema or allergic rhinitis) are at a greater risk of 123 
developing HL in earlier life and whether HL risk varied according to steroid exposure. 124 
  125 
METHODS 126 
Study design and setting: 127 
We conducted a matched case-control study using data from the UK Clinical Practice 128 
Research Datalink (CPRD), linked to Hospital Episode Statistic (HES) inpatient data and 129 
index of multiple deprivation (IMD) data. CPRD is an electronic health record database 130 
containing prospectively collected anonymised data from UK primary care consultations. It is 131 
the largest source of longitudinal primary care data, holding information on 22 million 132 
patients representing approximately 9% of the UK population (in 2013) (43). Data are 133 
available from 1987 onwards when CPRD was first established. It contains information on 134 
clinical symptoms, diagnoses (coded using Read codes), investigation results, medications 135 
and referrals to specialists. Practices contributing to CPRD are regularly audited to ensure 136 
high data quality and that 95% of prescribing and morbidity events are captured before 137 
practices are declared ‘up-to-standard’ (UTS) for research purposes (43). CPRD data used 138 
in this study were enhanced by pre-linkage to HES. The HES database contains records 139 
from every attendance at an NHS hospital in England (~125 million episodes per year). Each 140 
episode consists of clinical information on diagnoses, procedures and past medical history, 141 
coded in ICD10 (International Classification of Diseases, 10th revision). Data are available 142 
from April 1997 for patients in practices that have consented to data linkage (57% of all 143 
contributing CPRD practices in the UK) (44). CPRD data were additionally pre-linked to 144 
information on quintiles of IMD scores in practices that had consented to data linkage. These 145 
can be considered to represent a composite ecological (small-area based) measure of the 146 
socioeconomic status (SES) of a patient, based on the income, employment, disability, 147 
educational attainment and other attributes of the LSOA (Local Super Output Area) of a 148 
postcode. The latter typically comprise populations between 1,000 and 3,000 residents. All 149 
patients had an aggregate IMD score pertaining to the LSOA that their general practice is 150 
located. For this study, data were extracted from the July 2016 CPRD build and the Set 13 151 
linked data. 152 
Study population: 153 
Hodgkin’s lymphoma has a bimodal age-specific incidence pattern with the first peak 154 
occurring between 15-34 years (45). Individuals aged ≤50 years who were actively 155 
registered with a CPRD practice that had UTS data between January 1992 and July 2016 156 
were eligible for inclusion in the study. Individuals were excluded if they had a HL diagnosis 157 
prior to entry into the study, to avoid inclusion of retrospectively recorded past/prevalent 158 
cases; if they had no recorded IMD status; and if they had follow-up of less than one year in 159 
CPRD. 160 
 161 
Defining cases with HL 162 
All individuals in the study population with a first diagnosis of HL aged ≤50 years in either 163 
CPRD or HES during the study period were included as potential cases (see Supplementary 164 
Tables S1 for Read and ICD-10 code lists). The earliest recorded date of diagnosis was 165 
taken as the index date. Cases were excluded if the diagnosis was made within 1 year of 166 
registering with a CPRD practice (in accordance with previous studies to ensure that only 167 
incident HL diagnoses were identified) (46) or if there was no event date for the HL 168 
diagnosis. 169 
 170 
Defining matched controls 171 
Six controls for each case were selected, using individual matching on age at index date (±1 172 
year), sex and duration of active follow-up time (±2 years). A matched design was an 173 
efficient way to deal with the potential contributing effects of these variables. Concurrent 174 
sampling was used to match HL cases to controls who were HL-free at the index date of the 175 
case, while being under active follow up in an up-to-standard CPRD practice with a similar 176 
length of follow-up time prior to the index date. These individuals could not have a HL 177 
diagnosis at the time of matching (index date), but could go on to develop HL in the future. 178 
This method allowed ‘matching on time’ with cases in this dynamic population (47). Each 179 
control was assigned an index date corresponding to the diagnosis date in their matched 180 
case. 181 
 182 
Defining patients with allergic disease 183 
A diagnosis of allergic disease was defined as a coded diagnosis of asthma, eczema or 184 
allergic rhinitis in CPRD or HES at any point before the index date. As we are interested in 185 
both incident and prevalent cases of allergic disease, individuals with a diagnosis at any 186 
point in their medical record before the index date, were classed as having an allergic 187 
disease (see Supplementary Table S2 for Read and ICD-10 code lists). The total number of 188 
allergic diseases (with a maximum of three) and the date and age of first reporting of allergic 189 
disease diagnosis were recorded (categorised as infant (<1 years), childhood (1-17 years) or 190 
adult (≥18 years) onset).  191 
 192 
Defining corticosteroid use 193 
Corticosteroid use was defined as coded use of any corticosteroid (sub classified as inhaled, 194 
topical, oral or intravenous/intramuscular (IV/IM)) in CPRD at any point more than 6 months 195 
before the index date (see Supplementary Table S3 for code list). A ‘lag time’ of 6 month 196 
prior to the index date was used in line with previous studies to reduce the possibility of 197 
reverse causality in the months immediately prior to HL diagnosis, as early symptoms of 198 
undiagnosed HL might lead to steroid treatment in the period leading up to the diagnosis 199 
(48). Steroid use was further classified by frequency of use during follow up (total number of 200 
coded issues prior to 6m before index date). 201 
 202 
Covariates and mediators 203 
We used a directed acyclic graph to inform the identification of potential covariates and 204 
mediators and to avoid collider bias (Figure 1). The covariates included the matched 205 
variables age, sex and follow-up time, and SES (using quintiles of 2010 IMD). A prior 206 
diagnosis of IM or immunosuppressive conditions were also included based on a recorded 207 
diagnosis in HES or CPRD before the index date, as these are established risk factors for 208 
HL. For IM, codes for EBV infection, positive laboratory tests and IM caused by other viruses 209 
were included (Supplementary Table S4). When classifying immunosuppression, congenital, 210 
acquired and iatrogenic causes were included (see Supplementary Table S5 for code lists).   211 
 212 
Statistical analysis 213 
Primary analyses 214 
We initially described the baseline characteristics of cases and controls. Univariable 215 
conditional logistic regression (matched on age at index date, sex and follow-up duration) 216 
was used to generate odds ratios (OR) for the association between each of the exposure 217 
variables and HL, followed by multivariable conditional logistic regression adjusting for all 218 
other variables in the model. Interaction terms were subsequently introduced to investigate 219 
potential effect modification of the association between HL incidence and allergic disease by 220 
age, sex and SES. A further analysis was conducted on the final regression model, 221 
categorising allergic disease as a linear rather than binary variable to take into account the 222 
number of allergic diagnoses. We assessed for linear trend by number of allergic diagnosis, 223 
first by estimating the linear effect using likelihood ratio tests, and then investigating 224 
departure from linearity by comparing models in which allergic disease was added as a non-225 
linear vs. a linear term. We used 95% confidence intervals (CI) and an implied 5% level of 226 
statistical significance to minimise the risk of a type 1 error. 227 
We repeated the analyses with alternative exposure definitions where each allergic disease 228 
was considered separately. First we constructed a cross-tabulation comparing the frequency 229 
of combinations of allergic diseases in cases and controls. Then we repeated the conditional 230 
logistic regression analysis described above with asthma, eczema and allergic rhinitis 231 
included as separate variables to evaluate their independent effect on HL incidence after 232 
adjusting for each other and other variables in the model. Interaction terms were introduced 233 
to investigate for potential effect modification of the estimated risk associated with each 234 
allergic disease by age, sex and SES strata, and also other allergic disease. In 235 
supplementary analysis, for each of the three allergic diseases separately, using likelihood 236 
ratio tests we examined whether a model where they were categorized as infant / childhood / 237 
adult onset differed from a model where they were considered as yes-no variables 238 
independent of age of onset. Where there was evidence for heterogeneity, stratum-specific 239 
AORs were estimated.  240 
 241 
Secondary analyses 242 
A secondary analysis was conducted incorporating steroid use into the final model to assess 243 
for potential effect modification when stratifying by steroid use; and to investigate the extent 244 
to which the effect of variables may be confounded by steroid treatment, by comparing effect 245 
estimates before and after adjustment for steroid use. The effect of steroids was also 246 
assessed before and after adjustment for other variables, both collectively (any steroid use) 247 
and stratified by route of administration (inhaled, topical, oral or intravenous/intramuscular). 248 
We assessed for a potential dose-response relationship by estimating the linear effect of 249 
number of steroid prescriptions before the index date on HL risk and by route of 250 
administration (ordered according to strength/level of systemic absorption) using likelihood 251 
ratio tests as described above. 252 
 253 
Sensitivity analysis 254 
A sensitivity analysis was performed restricted to individuals with HES-linked data and effect 255 
estimates were compared to the estimates of the whole case-control population. Analyses 256 
were performed using Stata (version 15; StataCorp, College Station, TX, USA). 257 
  258 
RESULTS 259 
There were 1,236 incident cases of HL in this study individually matched to 7,416 controls. 260 
Table 1 shows the baseline characteristics of individuals in the case-control sample. Mean 261 
follow-up time was 6 years. Cases were more likely to be immunosuppressed (1% vs 0.2%), 262 
have a history of IM (4% vs 2%) and a diagnosis of at least one of the 3 allergic diseases 263 
(41% vs 33%) (Table 1). Treatment with steroids was more commonly seen in cases than in 264 
controls for all routes of administration, with significantly more cases having 2 or more 265 
steroid prescriptions during follow-up when compared to controls (43% vs 34%, p<0.001) 266 
(Table 1). Cross-tabulation of combinations of allergic diseases showed increased 267 
prevalence of asthma (19% vs 15%), eczema (21% vs 16%) and asthma and eczema 268 
combined (7% vs 4%) in cases compared to controls (Table 2).  The distribution of all other 269 
exposure variables did not differ substantially between cases and controls (Table 1).  270 
Immunosuppression 271 
Immunosuppression was by far the strongest risk factor for HL incidence in this study. 272 
Immunosuppressed individuals had 6 times greater odds of developing HL on univariable 273 
analysis (p<0.001). There was very little change in OR after adjusting for other variables, 274 
indicating the effect was independent of SES, allergic disease and IM (Adjusted OR (AOR) 275 
6.18, 95%CI 3.04–12.57, p<0.001). A slight attenuation in the OR was noted after adjusting 276 
for steroid use (AOR 6.05, 95%CI 2.97 – 12.33, p<0.001), indicating that part of the effect of 277 
immunosuppression on HL risk may be attributable to steroid use (Table 3).  278 
Infectious Mononucleosis 279 
IM was associated with double the odds of developing HL on univariable analysis (p<0.001). 280 
There was minimal attenuation of the effect in the mediation models after adjusting for 281 
immunosuppression, SES and allergic disease (AOR 1.89, 95%CI 1.33–2.68, p<0.001); and 282 
negligible change in the OR after adjusting for steroid use (Table 3). This indicates the effect 283 
of IM on HL is independent of these variables.   284 
 285 
Allergic Disease 286 
A previous diagnosis of one of more allergic diseases was associated with 1.4–fold greater 287 
odds of developing HL (p<0.001), with minimal change after adjusting for other variables 288 
(AOR 1.41, 95%CI 1.24–1.60), p<0.001) (Table 3). The risk of HL increased with increasing 289 
number of allergic diagnoses (p linear trend <0.001) (Table 4). When analysing by specific 290 
allergic disease type, eczema and asthma were associated with increased risk of developing 291 
HL (AOR 1.41, 95%CI 1.20–1.65, p<0.001; AOR 1.23, 95%CI 1.04–1.45, p=0.016, 292 
respectively) with no evidence of an association between allergic rhinitis and HL (Table 4).  293 
In supplementary analysis comparing age of allergic disease onset, asthma and allergic 294 
rhinitis had similar average age of onset in cases and controls. However, for eczema the 295 
median age of onset was 15 years in controls and 20 years in cases (p=0.004). Relatedly, 296 
there were significantly more incidences of adult onset eczema among cases than controls 297 
(54% vs 44%, supplementary table S6), with strong evidence that the effect of eczema on 298 
HL risk differed according to age of eczema onset (p=0.006). Only adult onset eczema was 299 
associated with increased odds of HL (AOR 1.73, 95%CI 1.40 – 2.13, p<0.001, 300 
supplementary table S7). There was no evidence of heterogeneity of effect estimates by age 301 
of onset for asthma or allergic rhinitis (p=0.33 and 0.27, respectively, data not shown). 302 
In the secondary analysis, after adjusting for steroid use, the associations between allergic 303 
disease and eczema with HL were attenuated, but still found to be significant (AOR 1.25, 304 
95%CI 1.09–1.43, p=0.002; AOR 1.27, 95%CI 1.08–1.49, p=0.005, respectively) (Table 3 305 
and 4). In asthmatics, after adjustment for steroids there was no increased risk of HL (Table 306 
4). There was no difference in effect estimates when stratifying by steroid use (Table 5) and 307 
there was no evidence of effect modification by age at index date, sex or SES (test for 308 
interaction p=0.12, 0.063 and 0.41 respectively – additional analyses not shown in tables).  309 
  310 
Corticosteroid use 311 
Previous steroid use for any indication was associated with increased risk of HL. Individuals 312 
with a history of steroid use at any time prior to 6 months before the index date had 1.5–fold 313 
increased odds of developing HL (OR 1.51, 95%CI 1.33–1.72, p<0.001). All routes of 314 
administration were associated with increased risk, with the strongest associations seen for 315 
IV/IM, followed by oral, topical and then inhaled steroids (Table 4). After adjusting for other 316 
variables, including allergic disease and other immune conditions, steroid use remained a 317 
significant risk factor for HL development (AOR 1.38, 95%CI 1.20–1.59, p<0.001) and this 318 
was seen for all routes of administration except for inhaled steroids (Table 4). 319 
 320 
Sensitivity analysis 321 
Restricting the analysis to patients who had HES-linked data available (59.6% of all patients 322 
in this study) gave similar effect estimates for variables across all regression analyses. 323 
DISCUSSION 324 
This study shows that allergic disease and steroid use for any indication are associated with 325 
an increased risk of developing HL before the age of 50. A previous diagnosis of eczema, 326 
but not asthma or allergic rhinitis, is associated with development of HL, this effect being 327 
concentrated in patients with adult onset eczema. This effect does not differ by steroid 328 
exposure and persists after adjustment for steroid use. Previously established risk factors for 329 
HL involving immune dysfunction were also found in this study to be important risk factors for 330 
HL in early life. Immunosuppressed individuals had a 6-fold increased odds of developing HL 331 
and those with a history of IM had almost double the odds.  332 
 333 
Comparison with the literature 334 
The associations between allergic conditions and HL have been inconsistent and 335 
inconclusive in the literature (see supplementary table S8). Söderberg et al. conducted a 336 
Swedish population-based case-control study of 2,394 HL cases that found asthma was 337 
associated with a 40% reduced risk of HL (25). This study relied hospital discharge summary 338 
data, which are likely to include only severe asthma, and results were based on only 18 339 
exposed cases. Vineis et al. conducted an Italian population-based case-control study that 340 
reported a 50% reduced risk of HL in individuals with allergic rhinitis, but no effect of asthma 341 
or eczema (30). This was a small study of 354 cases and relied on face-to-face interviews of 342 
adult cases, which may introduce recall bias of childhood exposures. Cozen et al. carried out 343 
a twin-study comparing 188 HL-discordant twin pairs in the USA using questionnaires (31). 344 
This found eczema was associated with a four-fold increased risk of HL, but was based on 345 
only 19 discordant pairs for the exposure. A number of further studies have concluded no 346 
association between allergic disease and HL risk (24, 32-35). These were small-scale case-347 
control studies of up to 585 cases and relied on retrospectively collected exposure data from 348 
telephone interviews and questionnaires. Misclassification is therefore likely owing to 349 
exposures being self-reported. Additionally, many of the studies included a diagnosis of HL 350 
at any age, which could produce misleading results as studies have shown HL in individuals 351 
aged <50 and >50 are likely to have different etiologies and may even be two separate 352 
disease entities (49-51). 353 
Existing studies on steroid use and HL are also limited and have produced conflicting 354 
findings. One study found an increased risk of any lymphoma with oral steroid use, but no 355 
increased risk with topical steroids after adjusting for other factors (39). A second study 356 
focusing specifically on HL found no increased risk, even at considerable and cumulative 357 
doses of oral steroids, however this study focused on HL cases aged over 50 years (41). 358 
Some further studies of topical steroid use have shown increased HL risk in a dose-359 
response fashion with increasing duration of exposure and potency (38, 40), but other have 360 
shown no increased risk even with moderate/highly potent topical steroids (42).  361 
 362 
Strengths and limitations 363 
We know of no previous studies assessing the association between allergic diseases with 364 
HL using prospectively collected population-based primary care electronic health records 365 
data and considering the potential interplay with steroid treatment. CPRD data are 366 
representative of the UK population across a number of demographic variables (43), which 367 
supports the external validity of the findings. Allergic conditions are predominantly diagnosed 368 
and treated in primary care, making GP electronic health records an ideal setting for 369 
examining them. Recording of asthma diagnosis in CPRD has high validity against gold 370 
standard diagnosis, with a positive predictive value (PPV) of 86.4% (52). HL diagnoses have 371 
high validity in CPRD when compared to gold standard national cancer registration (NCR) 372 
data (PPV for lymphoma 89.6%, sensitivity 97.3%) (53). The combined use of primary and 373 
secondary care HES-linked data further improved validity of exposures and outcomes by 374 
supplementing GP records with hospital data to improve capture of diagnoses. We used 375 
detailed exploration of diagnostic codes, verified by two clinicians and crosschecking with 376 
existing code lists in the literature to further improve accuracy of diagnoses. Rates of allergic 377 
diseases and HL in the study population showed a similar distribution to that reported in the 378 
literature. The large study sample enabled the precise estimation of associations, providing 379 
adequate power to identify associations when the effect size is small. Prospectively collected 380 
data have low risk of recall bias, unlike other types of data used previous studies. 381 
As for all observational studies based on routine data, there is potential for confounding, bias 382 
and missing data. However, the high degree of concordance of CPRD data with the NCR 383 
means misclassification of HL is likely to be low in this study with good capture of cases. 384 
CPRD data do not include staging information, which precluded us exploring possible 385 
variation in effect estimates by stage at diagnosis. A degree of misclassification and 386 
underreporting of allergic diagnoses is likely but this non-differential misclassification would 387 
potentially bias towards the null, meaning that the observed estimates of associations 388 
between allergic diseases and HL will be conservative. Some patients who will have 389 
contracted EBV will not experience any symptoms leading to consultation; and some who 390 
do, will be misdiagnosed. These mechanisms would both similarly result in potential 391 
underestimation of effect estimates, as the two comparator groups (cases / controls) become 392 
more similar artefactually, therefore the findings for IM are likely conservative. Route of 393 
steroid administration was used as a proxy for steroid strength as a marker of a dose-394 
response relationship (it was not possible to directly estimate cumulative steroid exposure or 395 
exact doses). 396 
Implications 397 
We propose three potential explanations for the observed association between allergic 398 
disease and increased HL risk in early life identified in this study. The first is in support of the 399 
antigenic stimulation hypothesis for HL pathogenesis. Chronic over-activation of the immune 400 
response in individuals with allergic disease over time results in randomly occurring 401 
mutations in rapidly dividing lymphocytes. These may be carcinogenic or cancer promoting, 402 
leading to HL development in predisposed individuals. The second explanation is that 403 
allergic disease and HL development in TYAs share a common immune pathway in their 404 
development and when regulation of this pathway is disrupted the risk of subsequently 405 
developing both conditions increases. Some studies have proposed the PD-1 (programmed 406 
death 1) receptor pathway and its ligands (PD-L1 and PDL2) as a potential culprit, as its 407 
components have been linked to both allergic diseases and HL pathogenesis (6, 54-58). 408 
Further studies are required to ascertain the presence and components of common 409 
underlying pathways, which if identified could present new targets for therapeutic 410 
intervention for these conditions (59). The third explanation is that therapeutic treatment for 411 
allergic diseases, such as steroids, which could themselves affect immunity may increase an 412 
individual’s risk of developing HL either directly or by increasing the risk of contracting pro-413 
oncogenic infections such as EBV. Disruption of the skin barrier in eczema may also act in 414 
this way by increasing access to other viral pathogens. However, we observed that allergic 415 
disease was associated with increased odds of developing HL even after adjusting for 416 
steroids and IM history. Further studies should explore the potential interplay between 417 
eczema, other viral infections and HL risk. 418 
This study showed that steroid use for any indication is associated with increased risk of 419 
developing HL in this patient population. There was evidence of a possible dose-response 420 
effect by route of administration, with routes of higher systemic absorption associated with 421 
greater HL risk. Interestingly, although steroid use was more frequently observed in cases 422 
than controls, the effect of allergic disease on HL risk did not differ when stratifying by 423 
steroid use. This suggests the effects of steroids are not due to them being a marker of more 424 
severe allergic disease. Additionally, the association with steroids and HL persisted after 425 
adjusting for allergic diseases and other established risk factors included in the model, 426 
indicating their effect is not fully explained by these conditions. Possible explanations include 427 
that steroids may be an independent risk factor for HL and this is a genuine causal 428 
association; it is more likely however that steroids are a proxy for other immune diseases, 429 
which are independent risk factors for HL and occur more commonly in allergic individuals in 430 
this patient population. Previous studies have demonstrated evidence for a link between 431 
allergic diseases and other immune conditions in support of this hypothesis (60). Further 432 
studies are required to examine the timing, duration and dose-response relationships 433 
between steroid exposure and HL development and the role of other immune diseases to 434 
establish their role in HL development more clearly.  435 
 436 
Conclusions 437 
This study has identified allergic diseases, specifically eczema, and steroid use for any 438 
indication as risk factors for developing HL in early life. This is in addition to the established 439 
risk factors of immunosuppression and IM, which also cause immune dysfunction. These 440 
findings add to the growing evidence that immune dysregulation is central to the 441 
development of HL in early life and allergic disease in childhood may increase the risk of 442 
developing haematological malignancies in the future. 443 
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  608 
Figure legend: 609 
Figure 1: Directed acyclic graph (DAG) for the study. Solid lines indicate assumed associations 610 
from previous studies, dashed lines indicate proposed associations examined in the current analysis.  611 
  612 
Tables: 613 
 
Characteristics 
Cases of HL 
(n=1236) 
Controls 
(n=7416) 
P value¥ 
Mean years follow-up*  
(SD, range) 
6.03 
(5.00, 0.01-26.42) 
6.01 
(4.96, 0.00-26.87) 
0.9 
Male sex* 702 (56.8%) 4212 (56.8%) 1.00 
Age at start of follow-up (years)   0.98 
    0–10 208 (16.8%) 1265 (17.1%)  
    11–20 241 (19.5%) 1396 (18.8%)  
    21–30 357 (28.9%) 2129 (28.7%)  
    31–40 331 (26.8%) 2026 (27.3%)  
    41–50 99 (8.0%) 600(8.1%)  
Age at index date* (years)   1.00 
    0–10  35 (2.8%) 210 (2.8%)  
    11–20 239 (19.3%) 1434 (19.3%)  
    21–30 337 (27.3%) 2002 (27.3%)  
    31–40 355 (28.7%) 2129 (28.7%)  
    41–50 270 (21.8%) 1621 (21.9%)  
IMD quintile   0.09 
    5 (most deprived) 251 (20.3%) 1598 (21.6%)  
    4 277 (22.4%) 1641 (22.1%)  
    3 246 (19.9%) 1442 (19.4%)  
    2 221 (17.9%) 1325 (17.9%)  
    1 (least deprived) 241 (19.5%) 1410 (19.0%)  
Immunosuppression 16 (1.3%) 15 (0.2%) <0.001 
Infectious mononucleosis 43 (3.5%) 131 (1.8%) <0.001 
Allergic disease♭ 500 (40.5%) 2429 (32.8%) <0.001 
Steroid use 731 (59.1%) 3714 (50.1%) <0.001 
    Inhaled 294 (23.8%) 1548 (20.9%)  0.02 
    Topical 604 (48.9%) 3011 (40.6%)  <0.001 
    Oral 110 (8.9%) 449 (6.1%) <0.001 
    IV/IM 30 (2.4%) 112 (1.5%) 0.02 
No. of steroids   <0.001 
    0 505 (40.9%) 3702 (49.9%)  
    1 201 (16.3%) 1178 (15.9%)  
    ≥2 530 (42.9%) 2536 (34.2%)  
Median no. of steroids  
(IQR) 
1 (0 – 4) 1 (0 – 3) <0.001 
Table 1: Baseline characteristics of cases with Hodgkin’s Lymphoma and controls. HL, Hodgkin’s 614 
Lymphoma; ¥ p value from chi-squared test or Mann-Whitney U-test for continuous variables; * 615 
matched variables; SD, standard deviation; ♭Defined as diagnosis of asthma, and/or eczema and/or 616 
allergic rhinitis during follow-up period. 617 
  618 
Concurrent Allergic Diagnoses in Cases (n=1,236) 
 
Asthma Eczema Allergic Rhinitis All three 
Asthma 18.9% (233) 6.6%(82) 4.6%(57)  
Eczema 6.6%(82) 21.0% (260) 4.4%(55)  
Hay fever 4.6%(57) 4.4%(55) 13.9% (172)  
All three        2.4%(29) 
Concurrent Allergic Diagnoses in Controls (n=7,416) 
Asthma 15.2% (1129) 4.4%(323) 4.2%(308)  
Eczema 4.4%(323) 15.6%(1154) 3.2%(241)  
Hay fever 4.2%(308) 3.2%(241) 12.4%(918)  
All three        1.4%(100) 
P Value* 0.001 <0.001 0.13  
Table 2: Frequency of concurrent allergic diseases: Proportion of cases and controls with a diagnosis 619 
or one or more allergic conditions. n, number; * P value for chi-squared test comparing allergic 620 
disease in cases and controls. 621 
  622 
  
Variable 
Univariable OR 
(95% CI) 
Adjusted OR♭ 
(95%CI) 
OR after adjustment for 
steroids (95% CI) 
Immunosuppression 6.36(3.15-12.87) 6.18(3.04-12.57) 6.05(2.97-12.33) 
p value <0.001 <0.001 <0.001 
Infectious mononucleosis 2.00(1.41-2.84) 1.89(1.33-2.68) 1.87(1.31-2.67) 
p value <0.001 <0.001 0.001 
Allergic disease 1.42(1.25-1.62) 1.41(1.24-1.60) 1.25(1.09-1.43) 
p value <0.001 <0.001 0.002 
Deprivation quintile    
    5 (most deprived) ref ref ref 
    4 1.08(0.89-1.29) 1.09(0.90-1.30) 1.08(0.90-1.30) 
    3 1.09(0.90-1.32) 1.08(0.89-1.31) 1.07(0.89-1.30) 
    2 1.06(0.87-1.29) 1.05(0.86-1.28) 1.04(0.86-1.27) 
    1 (least deprived) 1.09(0.90-1.32) 1.06(0.88-1.29) 1.05(0.87-1.28) 
p value 0.47* 0.69* 0.75* 
Steroid use 1.51(1.33-1.72) 1.38(1.20-1.59) – 
p value <0.001 <0.001 – 
Table 3: Association between exposures and Hodgkin’s Lymphoma incidence (≤50 years). OR, odds 623 
ratio; CI, confidence interval; ♭?matched on age, sex and follow-up time and adjusted for other 624 
variables in the model (region, deprivation, immunosuppression, atopy and infectious mononucleosis); 625 
p value from Likelihood-ratio Test; *p value for test for linear trend. 626 
  627 
 Variable Univariable OR Adjusted OR♭? OR after adjustment for 
steroids 
Asthma 1.31(1.11-1.53) 1.23(1.04-1.45) 1.15(0.97-1.36) 
p value 0.001 0.016 0.11 
Eczema 1.47(1.26-1.72) 1.41(1.20-1.65) 1.27(1.08-1.49) 
p value <0.001 <0.001 0.005 
Allergic rhinitis 1.15(0.96-1.37) 1.06(0.88-1.27) 0.99(0.83-1.19) 
p value 0.13 0.56 0.94 
Immunosuppression 6.36(3.15-12.87) 6.05(2.98-12.30) 5.94(2.91-12.10) 
p value <0.001 <0.001 <0.001 
Infectious mononucleosis 2.00(1.41-2.84) 1.88(1.32-2.68) 1.87(1.31-2.66) 
p value <0.001 <0.001 0.001 
Steroid use 1.51(1.33-1.72) 1.39(1.21-1.60) – 
p value <0.001 <0.001 – 
Topical steroid 1.46(1.28-1.66) 1.34(1.17-1.54) – 
p value <0.001 <0.001 – 
Inhaled steroid 1.20(1.03-1.39) 1.03(0.87-1.23) – 
p value 0.017 0.73 – 
Oral steroid 1.54(1.23-1.92) 1.30(1.02-1.65) – 
p value <0.001 0.036 – 
IV/IM steroid 1.63(1.08-2.46) 1.55(1.03-2.35) – 
p value 0.019 0.037 – 
Number of steroids 1.01(1.00-1.01) 1.00(1.00-1.01) – 
 
0.003 0.37 – 
No. of atopic diseases    
    0 ref ref ref 
    1 1.43(1.24-1.64) 1.42(1.23-1.63) 1.27(1.09-1.47) 
    2 1.30(1.04-1.63) 1.27(1.01-1.60) 1.10(0.87-1.39) 
    3 2.05(1.34-3.13) 2.04(1.34-3.13) 1.75(1.14-2.68) 
p value* <0.001 <0.001 0.005 
Table 4: Association between atopic diseases and Hodgkin’s Lymphoma incidence (<50 628 
years). OR, odds ratio; CI, confidence interval; p value from Likelihood-ratio Test; ♭?matched on age, 629 
sex and follow-up time and adjusted for other variables in the model (socioeconomic status, 630 
immunosuppression, atopic diseases and infectious mononucleosis); No., number;  ref, reference 631 
group; *p value for test for linear trend. 632 
 Variable Used steroid 
Adjusted OR♭?
(95%CI) 
Never used steroids 
Adjusted OR♭?
(95%CI) 
P value for effect 
modification 
Allergic disease 1.17(0.99-1.37) 1.48(1.15-1.90)  
p value 0.064 0.002 0.12 
Asthma 1.00(0.83-1.21) 1.85(1.34-2.56)  
p value 0.99 <0.001 0.002 
Eczema 1.27(1.07-1.51) 1.27(0.81-1.99)  
p value 0.007 0.31 0.99 
Allergic rhinitis 0.96(0.78-1.18) 1.14(0.77-1.71)  
p value 0.69 0.51 0.45 
Immunosuppression 9.08(3.59-22.96) 2.67(0.71-10.10)  
p value <0.001 0.15 0.12 
Infectious mononucleosis 1.82(1.17-2.83) 1.96(1.08-3.56)  
p value 0.008 0.028 0.85 
Table 5: Association between allergic diseases and Hodgkin’s Lymphoma incidence stratified 633 
by steroid use. OR, odds ratio; CI, confidence interval; p value from Likelihood-ratio Test; ♭?matched 634 
on age, sex and follow-up time and adjusted for other variables in the model (socioeconomic status, 635 
immunosuppression, atopic diseases and infectious mononucleosis). 636 

